A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Ald… (NCT07470983) | Clinical Trial Compass
RecruitingPhase 2
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
China60 participantsStarted 2026-04-23
Plain-language summary
This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female, aged ≥ 18 years on the date of signing the informed consent form.
✓. Diagnosed with primary aldosteronism.
✓. No use of antihypertensive drugs before screening, or stable use of antihypertensive drugs.
✓. Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures, and possible adverse reactions, and be capable and willing to comply with the protocol requirements to complete the study.
✓. From the signing of the informed consent form until 4 weeks after the last dose, the participant has no plan for procreation and is willing to adopt the highly effective contraceptive measures specified in the protocol.
Exclusion criteria
✕. Has known secondary causes of hypertension.
✕. Has previously undergone, or plans to undergo during the study period, adrenal-related surgeries, including adrenalectomy, adrenal ablation, etc.
✕. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m².
✕. Has had any malignancy of an organ system within 5 years before screening.
✕. Has received any other investigational drug within 90 days or 5 half-lives before screening (whichever is longer).
✕. Has a history of blood donation or blood loss ≥ 400 mL within 3 months before screening, or has received a blood transfusion within 2 months.
What they're measuring
1
Change from baseline in office systolic blood pressure (SBP);
✕. Women who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential unable to adopt highly effective contraceptive measures; or men unable to adopt highly effective contraceptive measures.